Clinical trial
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment…
NCT02510261 · Alnylam Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT02510261 |
|---|---|
| Title | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) |
| Official title | A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study |
| Lead sponsor | Alnylam Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Amyloidosis |
| Intervention type | Drug |
| Interventions | Patisiran |
| Enrollment | 211 |
| Start date | Jul 16, 2015 |
| Primary completion | Nov 23, 2022 |
| Completion | Nov 23, 2022 |
| First posted | Jul 29, 2015 |
| Last update posted | Dec 6, 2023 |
| Countries | Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, Malaysia, Mexico and 9 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: